Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on policy environment, global market, Chinese market, as well as the latest developments of domestic key enterprises related to China’s monoclonal antibody industry. Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and development of monoclonal antibody agents, which have achieved results in 2013. Hengrui Medicine Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and Qilu Pharm have applied for clinical research of monoclonal antibody agents. And Walvax Biotechnology Co., Ltd even made a huge investment in purchasing Genor Biopharma Co., Ltd, attempting to establish a large biological strategy. Although large-scale pharmaceutical enterprises entered monoclonal antibody field on a large scale, the overall innovation is still insufficient, and the market is represented by monoclonal antibody agents and biological analogue that have submitted applications, few imitated drugs, and innovative medicines are rare and precious things, mainly on account of high risks and long-time cycle. Due to late state, China’s strength on research and development will be still vulnerable within future three to five years, so it has to open the market preliminarily by depending on generic drugs. In 2013, the market size was CNY 3.8 billion around, up 30% year-on-year; product categories and sales volume were far less than that of European and American countries. According to statistical data of Shanghai Pharmaceutical Profession Association (SPPA), China will see four to six monoclonal antibody agents by 2016, such as Trastuzumab and Rituximab. And it is expected by 2020, six to ten monoclonal antibody agents will be listed in market, and some of which are independently researched drugs. Huidian Research believes that China’s monoclonal antibody market will embrace its first climax from 2017 to 2020.